OYLER JOHN 4

What Happened
John Oyler, CEO of BeOne Medicines (ONC), received two grants of performance share units on 2026-03-06 totaling 444,912 ordinary shares: 326,976 shares (vest in 2027) and 117,936 shares (vest in 2028). Both grants are reported as acquired at $0 (no cash paid). The awards are unvested and include accelerated vesting provisions upon a change of control or certain termination events.

Key Details

• Transaction date: 2026-03-06; Form 4 filed 2026-03-10 (filed within the typical two-business-day window).
• Grants: 326,976 shares (footnote F1, vests 2027) and 117,936 shares (footnote F2, vests 2028). Total = 444,912 shares. Price: $0.
• Shares owned after transaction: not specified in the provided excerpt.
• Notable footnotes: F1/F2 describe vesting schedules and accelerated vesting on change of control/termination. Other footnotes (F3–F7) in the filing note certain securities held in trusts/IRAs for which Oyler disclaims beneficial ownership.

Context
These are performance-based equity awards (not open-market purchases or sales). They represent future compensation contingent on service and/or performance and do not reflect an immediate cash investment by the insider. For retail investors, awards signal executive compensation/retention practices rather than direct insider buying or selling of existing stock.